Table 2 Expression of the tested immune-related markers separately in tumor cells and immune cells, and its clinicopathological significance

In tumor cells

PD-1

–

–

–

Positive (N = 0)

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

Negative (N = 227)

154 (67.8%)

73 (32.2%)

189 (83.3%)

38 (16.7%)

62 (27.3%)

165 (72.7%)

PD-L1

0.779

0.038

0.342

Positive (N = 46)

32 (69.6%)

14 (30.4%)

43 (93.5%)

3 (6.5%)

10 (21.7%)

36 (78.3%)

Negative (N = 181)

122 (67.4%)

59 (32.6%)

146 (80.7%)

65 (19.3%)

52 (28.7%)

129 (71.3%)

PD-L2

0.324

0.299

0.723

Positive (N = 197)

136 (69.0%)

61 (31.0%)

166 (84.3%)

31 (15.7%)

53 (26.9%)

144 (73.1%)

Negative (N = 30)

18 (60%)

12 (40%)

23 (76.7%)

7 (23.3%)

9 (30.0%

21 (70.0%)

IDO

0.313

0.884

0.711

Positive (N = 129)

84 (65.1%)

45 (34.9%)

107 (82.9%)

22 (17.1%)

34 (26.4%)

95 (73.6%)

Negative (N = 98)

70 (71.4%)

28 (28.6%)

82 (83.7%)

16 (16.3%)

28 (28.6%)

70 (71.4%)

TIM3

0.091

0.182

0.597

Positive (N = 109)

68 (62.4%)

41 (37.6%)

87 (79.8%)

22 (20.2%)

28 (25.7%)

81 (74.3%)

Negative (N = 118)

86 (79.2%)

32 (27.1%)

102 (86.4%)

16 (13.6%)

34 (28.8%)

84 (71.2%)

OX40

0.011

 < 0.001

0.665

Positive (N = 82)

47 (57.3%)

32 (42.7%)

56 (68.3%)

26 (31.7%)

21 (25.6%)

61 (74.4%)

Negative (N = 145)

107 (73.8%)

38 (23.2%)

133 (91.7%)

12 (8.3%)

41 (28.3%)

104 (71.7%)

OX40L

0.203

0.016

0.648

Positive (N = 86)

54 (29.1%)

32 (37.2%)

65 (75.6%)

21 (24.4%)

22 (25.6%)

64 (74.4%)

Negative (N = 141)

100 (70.9%)

41 (62.8%)

124 (87.9%)

17 (12.1%)

40 (28.4%)

101 (71.6%)

B7-H2

0.671

0.878

0.257

Positive (N = 193)

132 (68.4%)

61 (31.6%)

161 (83.4%)

32 (16.6%)

50 (25.9%)

143 74.1%)

Negative (N = 34)

22 (64.7%)

12 (35.3%)

28 (82.4%)

6 (17.6%)

12 (35.3%)

22 (64.7%)

In immune cells

PD-1

0.320

0.495

0.282

Positive (N = 126)

82 (65.1%)

44 (34.9%)

103 (81.7%)

23 (18.3%)

38 (30.2%)

88 (69.8%)

Negative (N = 101)

72 (71.3%)

29 (28.7%)

86 (85.1%)

15 (14.9%)

24 (23.8%)

77 (76.2%)

PD-L1

0.216

0.024

0.795

Positive (N = 91)

66 (72.5%)

25 (27.5%)

82 (90.1%)

9 (9.9%)

24 (26.4%)

67 (73.6%)

Negative (N = 136)

88 (64.7%)

48 (35.3%)

107 (78.7%)

29 (21.3%)

38 (27.9%)

98 (72.1%)

PD-L2

0.519

0.459

0.455

Positive (N = 108)

71 (65.7%)

37 (34.3%)

92 (85.2%)

16 (14.8%)

32 (29.6%)

76 (70.4%)

Negative (N = 119)

83 (69.7%)

36 (30.3%)

97 (81.5%)

22 (18.5%)

30 (25.2%)

89 (74.8%)

IDO

0.451

0.642

0.536

Positive (N = 154)

102 (66.2%)

52 (33.8%)

127 (82.5%)

29 (17.5%)

44 (28.6%)

110 (71.4%)

Negative (N = 73)

52 (71.2%)

21 (28.8%)

62 (84.9%)

11 (15.1%)

18 (247%)

55 (75.3%)

TIM3

0.031

0.355

0.472

Positive (N = 104)

63 (60.6%)

41 (39.4%)

84 (80.8%)

20 (19.2%)

26 (25.0%)

78 (75.0%)

Negative (N = 123)

91 (74.0%)

32 (26.0%)

105 (85.4%)

18 (14.6%)

36 (29.3%)

87 (70.7%)

OX40

0.040

0.003

0.211

Positive (N = 84)

50 (59.5%)

34 (40.5%)

62 (73.8%)

22 (26.2%)

27 (32.1%)

57 (67.9%)

Negative (N = 143)

104 (72.7%)

39 (27.3%)

127 (88.8%)

16 (11.2%)

35 (24.5%)

108 (75.5%)

OX40L

0.093

0.931

0.079

Positive (N = 103)

64 (62.1%)

39 (37.9%)

86 (83.5%)

17 (16.5%)

34 (33.0%)

69 (67.0%)

Negative (N = 124)

90 (72.6%)

34 (27.4%)

103 (83.1%)

21 (16.9%)

28 (22.6%)

96 (77.4%)

B7-H2

0.153

0.278

0.992

Positive (N = 150)

97 (64.7%)

53 (35.3%)

122 (81.3%)

29 (18.7%)

41 (27.3%)

109 (72.7%)

Negative (N = 77)

57 (74.0%)

20 (26.0%)

67 (87.0%)

10 (13.0%)

21 (27.3%)

56 (72.7%)